This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

June 22-24, 2021
Delivered in a 100% Virtual Format,
Pacific Standard Time (PST)

CAR and T Cell Therapies: Pioneering point of care with innovative manufacturing and commercialization strategies

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors

2021 Agenda

Stay Tuned for the 2021 agenda, due to be released in early February! Sign up for email updates to be the first to view the 2021 agenda


Novel Technological Advances & Applications in Genome Editing

Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes
Enabling more Precise, Efficient and Safer Genome Editing & Quantifying its Outcomes
  • Get to grips with the repurposing of CRISPR-Cas 9 and all its variants  
  • Exchange ideas on tools for on and off target effects when using different enzymes & variants
  • Understanding on-target cutting – analyzing events at the intended site
Novel Gene Editing Applications in CART
Novel Gene Editing Applications in CART
  • Understand next generations technologies in adoptive T cell immunotherapy
  • Prepare for allo CAR & T Cell Therapies – iPSc, Gene editing & highly characterized products
  • Build controls for product quality & specifications around gene editing
Delivery, Administration & Editing Applications for Genetic Disease
Delivery, Administration & Editing Applications for Genetic Disease
  • Get to grips with non-viral delivery methods including nano injection, nanoparticles and more…
  • Simplify in vivo approaches to eye disease & DMD treatment
  • Discuss CRISPR and potential treatment strategies in blood and liver disorders


Our 2020 attendees had access to all of the extensively researched agenda and sessions with the novelty of being able to view it at their own pace. How? All presentations was made available both live and on-demand for 30 days, so attendees was able to attend more presentations than ever before!

TAC T-cells leverage the Natural TCR’s properties, Have an Improved Safety Profile Compared to CAR-T cells and are Efficacious in Solid Tumors

Sabine Chlosta, Chief Medical Officer, Triumvira, USA

Developing Allogeneic CAR T-cells that Lack Host Reactivity and can Resist Rejection to Improve their Safety and Persistence

David Quach, Instructor, Center for Cell and Gene Therapy, Baylor College of Medicine, USA

Repurposing of CRISPR-Cas 9 and the Potential of Cas and all its Variants

Ross Wilson, Project Scientist & PI, UC Berkeley and the Innovative Genomics Institute, USA

Manufacturing Concepts for Gene-Edited Allogeneic CAR-T Cell Products 

Wenzhong Guo, VP, Cell Therapy, Sorrento Therapeutics, USA

The Impact of Allogeneic Approaches on Patient Access to CAR T

Christopher R. Heery, Chief Medical Officer, Precision BioSciences, USA

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets

Anthony Conway, Senior Manager, Cell Therapy, Research Department, Sangamo Therapeutics, USA


Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

Contact Jennifer Wickett: | +18575046694